

# Central Lancashire Online Knowledge (CLoK)

Title	Neuroimmune alterations in autism: a translational analysis focusing on the animal model of autism induced by prenatal exposure to valproic acid
Туре	Article
URL	https://clok.uclan.ac.uk/id/eprint/24033/
DOI	https://doi.org/10.1159/000492113
Date	2018
Citation	Deckmann, Iohann, Schwingel, Gustavo Brum, Fontes-Dutra, Mellanie, Bambini-Junior, Victorio and Gottfried, Carmem (2018) Neuroimmune alterations in autism: a translational analysis focusing on the animal model of autism induced by prenatal exposure to valproic acid. Neuroimmunomodulation. ISSN 1021-7401
Creators	Deckmann, Iohann, Schwingel, Gustavo Brum, Fontes-Dutra, Mellanie, Bambini-Junior, Victorio and Gottfried, Carmem

It is advisable to refer to the publisher's version if you intend to cite from the work. https://doi.org/10.1159/000492113

For information about Research at UCLan please go to <a href="http://www.uclan.ac.uk/research/">http://www.uclan.ac.uk/research/</a>

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <u>http://clok.uclan.ac.uk/policies/</u>

- 1 Neuroimmune alterations in autism: a translational analysis focusing on
- 2 the animal model of autism induced by prenatal exposure to valproic acid
- 3 Iohanna Deckmann<sup>1,2,3</sup>, Gustavo Brum Schwingel<sup>1,2,3</sup>, Mellanie Fontes-
- 4 Dutra<sup>1,2,3</sup>, Victorio Bambini-Junior<sup>1,3,4</sup> and Carmem Gottfried<sup>1,2,3\*</sup>
- 5 1 Translational Research Group in Autism Spectrum Disorders-GETTEA,
- 6 Universidade Federal do Rio Grande do Sul -UFRGS, 90035-003 Porto Alegre,
   7 RS, Brazil.
- 8 2 Neuroglial Plasticity Group, Department of Biochemistry, Universidade
- 9 Federal do Rio Grande do Sul -UFRGS, 90035-003 Porto Alegre, RS, Brazil.

3 National Institute of Science and Technology on Neuroimmunomodulation-INCT-NIM.

- 12 4 School of Pharmacology and Biomedical Sciences, University of Central
- 13 Lancashire, PR1 2HE, Preston, UK
- 14
- 15 \*CORRESPONDING AUTHOR:
- 16 CG (cgottfried@ufrgs.br)
- 17 Departamento de Bioquímica, ICBS, Universidade Federal do Rio Grande do
- 18 Sul, Ramiro Barcelos, 2600 21111. CEP: 90035-003. Porto Alegre-RS, Brazil.
- 19
- 20
- 21
- 22
- 23

#### 1 ABSTRACT (250 words)

Autism Spectrum Disorder (ASD) is a highly prevalent developmental disorder 2 3 characterized by deficits in communication and social interaction and in 4 stereotyped or repetitive behaviors. Besides the classical behavioral dyad, several comorbidities are frequently present in patients with ASD, such as 5 anxiety, epilepsy, sleep disturbances and gastrointestinal tract dysfunctions. 6 Although the etiology of ASD remains unclear, there is supporting evidence for 7 8 the involvement of both genetic and environmental factors. Valproic acid (VPA) is an anticonvulsant and mood stabilizer that, when used during the gestational 9 10 period, increases the risk of ASD in the offspring. The animal model of autism by 11 prenatal exposure to VPA shows construct and face validity, since several 12 changes seen in subjects with autism are also observed in the VPA animal model. Neuroimmune alterations are common both in autistic individuals and in animal 13 14 models of autism. In addition, exposure to pathogens during the pregnancy is a known risk factor for ASD, and maternal immune activation can lead to autistic-15 16 like features in animals. Thus, immunological alterations in pregnancy could affect the developing embryo, since immune molecules can pass through the 17 placental barrier. Here, we summarize important alterations in inflammatory 18 19 markers, such cytokines and chemokines in patients with ASD and in the VPA 20 animal model.

21

Keywords (3–9 key words): ASD, neuroimmune, cytokine, animal model,
valproic acid

#### 1 INTRODUCTION

2 Since the first descriptions, in the early 1940's by Leo Kanner and Hans 3 Asperger, new data has been shared to the scientific community about Autism 4 Spectrum Disorder (ASD) [1]. Currently, ASD is diagnosed by changes in two behavioral domains: a) communication and social interaction impairments in 5 6 multiple contexts, including deficits in social reciprocity, non-verbal 7 communication used for social interaction and in skills to initiate, maintain and 8 understand relationships; and b) Repetitive behaviors, restricted and stereotyped 9 activities [2].

10 There is no clinical marker or quantitative examination in peripheral tissues that can be used for an early diagnosis of this disorder [3]. Even though there are 11 12 many well accepted surveys for behavioral diagnosis, ASD is a highly complex and heterogeneous disorder, presenting distinct manifestations, in which two 13 14 individuals hardly share the same set of symptoms [4,5]. The large heterogeneity of the symptoms could potentially be explained by individual differences, for 15 16 example in the immune system. Alterations in cytokines levels are common in 17 autistic individuals, with a frequent observation of elevated levels of pro 18 inflammatory cytokines [6,7].

19 Genome-wide association studies (GWAS) have already described 20 interesting relations between immune system disruptions and neurological 21 disorders like autism and schizophrenia [8]. Specifically in ASD, an interesting 22 example is the dysregulated genes reported, as IL-1 $\beta$  and IL-12, both involved in 23 cytokine-cytokine receptor interaction [9]. One study relating ASD and 24 neuroimmune genetic disruption shows an alteration on glutamate receptor

1 metabotropic 5 (GRM5) single nucleotide polymorphisms (SNPs) [10], which is 2 not exactly a neuroimmunological alteration, but this gene is highly expressed in many neuronal regions implicated in ASD, besides acting on synaptic plasticity, 3 4 modulating innate immunity and microglia activation. When occurs a GRM5positive allosteric modulation, several negative behaviors described in ASD are 5 6 rescued, including stereotypies [10]. Taken together, the evidences showing 7 genes interaction and ASD diagnosis demonstrate important genetic contribution 8 in neuroimmunological imbalance in ASD. However, despite the data cited above, no gene was identified as an important actor in triggering this disorder. 9

According to the most recent epidemiological survey conducted in United States, the current incidence of ASD is 1:68 [11]. Although the etiology of ASD remains unknown, it is hypothesized that the onset of this disorder depends on the interplay between genetic and environmental factors. Epidemiological observations suggest that exposure to teratogens - especially in the first trimester of pregnancy - could be closely related to ASD development. An important example is the prenatal exposure to valproic acid (VPA) [12,13].

# 17 Valproic acid (VPA) and VPA animal model

The compound VPA is a drug widely used as an anticonvulsant and mood stabilizer in the treatment of epilepsy and bipolar disorder [13,14]. Although VPA is well tolerated and safe in adults, there is evidence of its teratogenicity [14]. Clinical studies over the years have shown that intrauterine exposure to VPA is associated with birth defects, cognitive impairments, and increased risk of autism [13]. In recent years, animal studies have investigated the anatomical, behavioral,

1 molecular, immunological and physiological outcomes related to exposure to2 VPA [13].

3 Epidemiological observations demonstrate a strong correlation between 4 prenatal exposure to VPA and ASD [15-18]. Based on these observations, an animal model for study of autism prenatally induced by VPA was established [19-5 6 21]. Behavioral studies show that exposure to VPA in rats and mice leads to 7 several autistic-like behaviors in male offspring, including social behavior deficits, 8 increased repetitive behaviors, and communication deficits similar to those found in ASD subjects [19-23], pointing out the animal model's translationality, as the 9 10 diagnosis of ASD is given through behavioral evaluation.

11 Since current diagnostic criteria for ASD are exclusively clinical and 12 resulted from behavioral analyses, the study of ASD in humans prior to the onset of symptoms becomes a very challenging task. Animal models provide the 13 14 opportunity for analyzing the developmental changes that can trigger ASD-like features [24,25]. They provide the possibility to study and manipulate biological 15 16 pathways for understanding and even preventing or reversing the appearance of 17 the morphological, functional and behavioral alterations found in ASD. In addition, 18 studies with animals can reveal some new important factors involved in the etiology of this disorder. 19

## 20 Histone-deacetylases inhibitors (HDACi) and neuroimmune alterations

Autism and many other psychiatric disorders, like schizophrenia, bipolar disorder and major depression present not only susceptibility to environmental risk factors, but also a high genetic influence [26,27]. In the last years, there is

growing evidence indicating that epigenetic alterations may have an important
 role in several psychiatric disorders.

3 Epigenetic regulation includes long-term changes, as DNA methylation, 4 and short-term changes, as modifications in histone proteins associated with DNA [28]. Histones are small basic proteins that act as spools around which DNA 5 winds, regulating the packaging of DNA and allowing or inhibiting gene 6 7 When the histone is acetylated by histone acetyltransferases expression. 8 (HATs), this local alteration leads to chromatin decondensation, promoting gene expression by the activation of the transcription machinery. On the other hand, 9 10 histone deacetylation - mediated by histone deacetylases (HDACs), results in 11 inhibition of transcription promoting a controlled gene expression [28,29].

12 Substantial epigenetic alterations were found in the regulatory regions of 13 many candidate genes for ASD, such as GABAergic genes, GAD67, Reelin, 14 Oxytocin receptor, BDNF, showing that the epigenetic component in ASD has been widely studied [26]. The histone post-translational modifications, as 15 16 acetylation and methylation, play a key role in the gene expression regulation 17 [30]. These characteristics are crucial for important biological processes like the 18 action of immune system, in which HDACs modulate gene expression of toll-like receptors and interferon signaling pathways [31]. 19

The HDAC inhibitors drugs play an important role in immune context. Studies showed an increased transcription of the major histocompatibility complex (MHC) class II, located in the tumor cell surface in mouse and humans [32], indicating an interesting effect on several immune cells. It leads to less viability of T CD4 cells and decreases the production of pro-inflammatory

cytokines, making the T CD8 cells increase the secretion of pro-inflammatory
 cytokines, modulating the activity of natural killer (NK), as well in cells and Treg
 cells [33].

4 Hence, several drugs used as antidepressants and mood stabilizer are characterized as HDAC inhibitors class. Valproate, a well-known HDAC inhibitor 5 6 drug, induces important delays in the neuronal maturation [34], already described 7 in ASD [35]. Moreover, VPA prenatal exposure alters the postnatal histone 3 (H3) 8 acetylation levels in cerebellum [36], stimulates glial cell proliferation in the 9 developing rat brain [37] and also induces changes in acetylation levels in 10 astrocytes of hippocampus and cortex in cell culture, more than other 11 antidepressants and mood stabilizer [38]. These unique effects of VPA, 12 especially in comparison to similar HDAC inhibitor drugs, indicate that the VPA molecule might have exclusive properties which are still unclear, although some 13 14 evidence indicates a possible VPA binding in the catalytic center of HDACs [39]. Those epigenetics alterations occur before the well described neuroimmune 15 16 alterations, and, thus, epigenetics mechanisms may be involved in the immune disturbance [36]. These data highlight the role of the valproic acid and HDAC 17 18 inhibitors as epigenetic modulators that could be underpinning the immunological 19 alteration, as well as the neurological outcomes, in psychiatric disorders.

# The intimate relationship between central nervous system and immune system

For a long time, immune and central nervous systems were considered compartments that operate separately and independently. However, recent studies demonstrate an active communication between these two systems,

1 modulating bi-directly each other with neurotransmitters and neuromodulators in 2 periphery. In addition, in a landmark study, lymphatic vessels were discovered in central nervous system, putting in check the current view of the brain as an 3 4 "immune privileged site" and raising new possibilities for the crosstalk between brain and immune system [40]. Anatomically the central nervous system (CNS) 5 6 is bathed by the cerebrospinal fluid (CSF) and surrounded by the meninges. 7 which contain lymphatic and blood vessels [41]. The brain parenchyma is 8 separated from the circulating blood by a blood-brain barrier (BBB), which 9 prevents the entry of pathogens, circulating immune cells, and other substances 10 from the blood.

11 The BBB is defined as a semipermeable membrane that separates the 12 circulating blood from the brain and extracellular fluid in the central nervous system [42]. CNS blood vessels interact with different peripheral and brain-13 14 resident immune cell populations, as perivascular macrophages and microglial cells, respectively. The BBB is formed by the concerted action of endothelial and 15 16 glial cells. During development, at embryonic day 10 (E10), initial clues for angiogenesis lead to the early properties of BBB in CNS by activation of the 17 18 Wnt/b-Catenin canonical pathway [43-45]. There is no consensus about the 19 exact time when the BBB is fully formed [46]. Nevertheless, at E15, pericytes, 20 which have crucial roles in BBB formation and maintenance, begin to interact intimately with endothelial cells (EC) in the capillary walls [47]. In postnatal life, 21 22 endothelial cells from brain capillaries are covered up by mature pericytes, sharing their basement membrane with endothelial cells [48]. Moreover, the 23 astrocytes project cellular terminations called "end feet" toward the capillaries, 24 25 providing the outer layer of the BBB. Pericytes and astrocytes also secrete

proteins involved in extracellular matrix formation and deposition of the basement
 membrane [48,49].

3 The presence of this limiting barrier allows the CNS to control and fine tune 4 the flow of a variety of molecules from periphery, regulating its permeability to seek homeostasis. In CNS physiology, there are extensive vessels where 5 6 monocytes, granulocytes and dendritic cells circulate [50]. In addition, the brain 7 parenchyma is populated with microglia, resident-cells from the immune lineage 8 that play crucial roles in brain surveillance and response against multiple types 9 of damage. Studies with rodents showed that, during neurodevelopment, specific 10 monocytes emerge at E7 and infiltrate the CNS at E9.5 as pre-macrophages, 11 expressing the chemotactic factor CX3C chemokine-receptor 1 (CRXCR1) [50]. 12 The presence of cytokines as interleukin-1 beta (IL-1 $\beta$ ) and tumor growth factor beta (TGF- $\beta$ ) allows the differentiation of pre-macrophages in early microglia at 13 14 E14.5, which then generate mature microglia at P14. In fact, TGF- $\beta$  seems to be crucial for microglial specification in CNS [51,52]. 15

16 Microglial cells are capable to interact with almost all cell types in the CNS 17 modulating cell maturation during development and promoting tissue repair and 18 homeostasis. Moreover, in postnatal life, microglia play crucial roles in sensing perturbations in encephalic environment, actively responding to even minor 19 20 pathological changes in CNS [53,54] by altering their shape and gene expression profile. The term "microglial activation" has been considered as a shift from a 21 22 "resting" stage to an "activated" state when disturbance of tissue homeostasis is detected or upon experimental stimulation. However, this term implies the 23 24 understanding of an "inactivated" phenotype when brain tissue is not facing any

changes in homeostasis. In fact, microglial cells are never inactive, showing 1 2 highly dynamic surveillance functions in CNS [50,55,56]. Many authors are suggesting to rename this surveillance state of microglial cells to "surveying 3 4 microglia", instead of "resting microglia" [50]. These cells can shift from their "surveying" or "resting" state to "activated" or "alerted" state when facing chances 5 6 in CNS homeostasis, as infections recognized by toll-like receptors [57], cell 7 damage or trauma. Recent studies have demonstrated that the 8 lipopolysaccharide (LPS) exposure downregulates the transcriptional factor Sal-9 like protein 1 (SALL1) and promotes several alterations in microglial identity, with 10 a concomitant upregulation of genes associated to other resident macrophages, 11 indicating that SALL1 might be important for maintenance of microglial identity in 12 response to immune challenge [50,58]. Once activated, microglial cells can 13 commit to different phenotypes called "reactive", having a large functional and 14 molecular diversity. These changes in microglia profile are correlated with the 15 type of challenge faced by the CNS. They can shift to a pro-inflammatory state 16 also called "M1 phenotype" [59] presenting highly phagocytic and neurotoxic 17 activities and releasing pro-inflammatory chemokines and cytokines in response 18 to an immune challenge, such as a microorganism invasion [60] or the presence of pro inflammatory signals [61–63]. Once the immune stimulator is controlled, 19 microglial cells are able to shift to a more neuroprotective profile called "M2 20 phenotype" which involves anti-inflammatory responses [59,64]. Nonetheless, 21 22 the activated pro-inflammatory profile can progress in pathological conditions. 23 Although the immune challenge and the brain environment are responsible for 24 the early microglial responses, signals from CNS resident and infiltrating immune 25 cells can shape reactive profiles of microglial cells and play important roles in

many brain diseases [65–69]. All these stimuli could direct microglia's fate to
alternative states, including microglial cell death, but there's still scarce
information about the course of microglial activation, their reversibility to the
surveying state [70] or the preservation of molecular memory of previous stimuli.
Moreover, cells that infiltrate from the blood and differentiated into microglia could
also return to the periphery [65,71].

7 There is a low basal entry of immune cells from blood periphery into the 8 CNS in normal conditions. Studies have shown that, although microglial cells play major roles in brain surveillance, the perivascular macrophages represent a 9 10 crucial immune regulator and sensor of perturbations in CNS and periphery. 11 These cells are derived from bone marrow and are intimately associated with the 12 bloodstream since they reside between endothelial cells and astrocyte's end feet [72-74]. This privileged location of perivascular macrophages allow them to 13 14 simultaneously monitor the blood and the brain interstitial fluid, providing a fine control of brain homeostasis and BBB integrity [72,75]. Although macrophages 15 16 display different locations, they can perform specific roles in these microenvironments. In addition to perivascular space, macrophages can be 17 18 located within choroid plexus and meningeal space. In choroid plexus, which is 19 considered the major site of CNS immune surveillance, there are tissue-resident 20 macrophages called epiplexus cells disposed alongside the fourth ventricle with 21 dendritic cells (DC), monocytes and mast cells [76,77]. Referred by many authors 22 as the "immune regulatory gate", the choroid plexus is capable to induce specific immune responses and allows cell migration between blood and CSF [78,79]. 23 24 The meningeal macrophages are positioned in the subdural meninges and act as 25 sentinel cells for damage and infection in brain tissue, surveying the

1 cerebrospinal fluid (CSF) and the extracellular lumen of meningeal blood vessels 2 [80,81]. Thus, macrophages play critical roles in CNS surveillance, homeostasis and disease. Nonetheless, there is a variety of other immune cell types in the 3 4 brain environment. In physiological condition, studies have observed the presence of monocytes in meningeal spaces, although more evidence is still 5 6 needed [82]. Granulocytes (neutrophils, mast cells, eosinophils, and basophils) 7 can be found in meningeal spaces with mast cells also present in brain 8 parenchyma [72,83]. These cells are highly phagocytic and play important roles 9 in response to brain infections and tissue damage [72,84,85]. Dendritic cells (DC), 10 the main antigen-presenting cells in periphery, can also be found in CNS. They 11 are located in the choroid plexus, meningeal space, and are specially abundant 12 in lymphatic vessels in meninges [86-88]. The presence around these vessels 13 suggests important roles for DC in inflammatory diseases and brain infections 14 [40].

15 During inflammatory condition, there is extensive infiltration of immune 16 cells in the CNS. The barriers that regulate cellular entry are the blood-brain barrier (BBB) within the CNS parenchyma, and the blood-cerebrospinal fluid 17 (blood-CSF) barrier within the choroid plexus" [89]. When brain homeostasis is 18 19 compromised, immune cells can infiltrate from the periphery to the brain 20 parenchyma due to the elevation in BBB permeability. This is generally observed and investigated in the context of a pathological CNS inflammatory response [90-21 22 92]. Under pathological conditions, microglia activation can lead to BBB disruption, allowing a substantial cellular infiltrate and amplifying the inflammatory 23 response [93,94]. One of the key mediators in these processes is the release of 24 25 cytokines and chemokines by periphery and brain-resident immune cells. This

novel view of the immune system as an active player in brain function is modifying
our current view of neuropsychiatric disorders. Immune alterations are now seen
as central for the pathophysiology of many brain diseases and further
understanding of this neuroimmune axis can result in new therapies and
diagnostic tools.

## 6 Neuroimmune alterations in ASD: from patients to the VPA animal model

7 In the last decade, the immune system has caught the attention of neuroscientists for the interplay between neurons and immune mediators, not 8 9 only in disease, but also in the homeostasis of the brain. In the past, the central 10 nervous system was called "an immune-privileged region", once the blood brain barrier controls the cross talking between brain and the periphery. However, 11 12 recent findings demonstrated that this privilege is not related to the absence of 13 immune modulation in brain activity and homeostasis, but a time-dependent 14 specific modulation in many regions during brain development [95]. Immune cells and immune molecules, such as cytokines and chemokines, can modulate 15 16 cognitive, emotional and behavioral processes, triggering different responses in neuronal and glial cells [96]. Cytokines are small signaling-molecules acting as 17 18 mediators of communication between immune cells. Their roles include stimulation and regulation of cell development, maturation and response against 19 20 immune challenges [97,98]. Chemokines can be characterized as a vast group of 8-10 kDa molecules from the super family of cytokines that induce chemotaxis 21 22 of immune cells. Once bound in their receptor, the complex chemokine-receptor can activate signaling cascades that induce immune cell trafficking to the target 23 24 area. Also, this complex plays important roles as molecular signal in crosstalk

among neuronal and glial cells and immune resident cells in nervous system, as
microglia [99,100]. Since chemokines are capable to target different types of
receptor, they can modulate different cell processes, including cell adhesion,
proliferation, phagocytosis, apoptosis, angiogenesis, cytokine secretion and T
cell activation [101].

6 Lymphocytes are cells capable of recognizing any foreign antigens displayed by antigen-presenting cells, constituting the main cells of adaptive 7 8 immunity [102]. Lymphocytes respond by proliferating and differentiating in 9 effector cells, whose function is the elimination of the pathogen and creation of 10 an immunological memory [103]. When naïve CD4+ T cells encounter specific 11 antigens, they can differentiate into a range of effector subgroups. Several 12 transcription factors are individually required for T-cell differentiation, generating a specific lineage that express characteristic cytokines. That is, once specific 13 14 transcription factors are activated, they promote differentiation of naïve T cells, which differentiate into specific immunological responses: Th1, Th2 and Th17. In 15 16 the presence of IFN-y and IL-12, Signal transducer and activator of transcription (STAT) 1 and STAT4 signal for the expression of the transcription factor T box 17 18 expressed in T cells (T-bet) and promotes response Th1. On the other hand, Th2 19 cell commitment occurs when IL-4 and STAT6 increase expression of GATA-20 binding protein (GATA3) transcription factor. The presence of TGF-β associated with IL-6 signaling via STAT3 generating the expression of retinoid-related 21 22 orphan receptor (RORyt) transcription factor, results in the differentiation of Th17 cells. Also, TGF-β, with IL-2 signaling via STAT5 is known to generate, at least 23 24 in vitro, inducible Treg cells, which express Foxp3 transcription factor (See Figure 25 1) [104].

The modulation of cytokine levels can alter significantly the brain 1 2 physiology and behavior. Recent studies highlight a link between immune dysfunction and behavioral impairments [105]. For example, the relation between 3 4 IL-6 and several altered behaviors has already been established in the literature [106–108]. Signs of neuroinflammation and altered inflammatory response are 5 6 seen in ASD subjects throughout life [109]. Therefore, some authors hypothesize 7 that the neuroimmune disturbances could be causal for ASD [110]. Below, we will 8 detail the main neuroimmunological findings (summarized in Tables 1 and 2) in ASD subjects and in VPA animal model of autism: 9

10 *IL-1β* 

IL-1β is a cytokine produced by fibroblasts, monocytes, tissue 11 12 macrophages, dendritic cells (DCs), B lymphocytes, epithelial cells, and natural killer (NK) cells [111] that promotes inflammation by indirectly stimulating 13 14 lymphocyte function and activating macrophages [112,113]. IL-1β has the ability to increase the expression of adhesion molecules such as VCAM-1 and ICAM-15 16 1, supporting the infiltration of inflammatory cells from the circulation into the 17 tissue and resulting in chronic IL-1-induced inflammation [112,113]. IL-1β 18 stimulates expression of inflammatory mediators and induces T-helper type 17 (Th17) response. Furthermore it can also play important roles as a mediator of 19 20 the anti-inflammatory response [112,113].

Both elevation and reduction in IL-1β levels have already been reported in
ASD subjects. Increased levels of IL-1β were found in plasma [114,115], serum
[116,117], and peripheral blood mononuclear cells (PBMCs) [118–120] whereas
decreased levels were described in neonatal dried blood samples (n-DBSS)

[121]. In VPA animal model, IL-1β was increased in hippocampus [122,123], in
 LPS-exposed hippocampus [109] and in whole brain homogenate [124].
 Increased levels of this cytokine are associated with increased stereotypy [120],
 one of the main characteristics of ASD.

5 IL-2

Interleukin-2 has an important role in controlling the survival of immature
and mature T cells [125] and is mainly secreted by CD8+ and CD4+ T cells after
recognition of the antigen and co-stimulators [111]. IL-2 is the most important
cytokine for promoting the clonal expansion of antigen-activated T cells [126].
The only report in ASD is a reduction of IL-2 levels in neonatal dried blood
samples (n-DBSS) [121].

12 *IL-4* 

IL-4 is the main cytokine of Th2 response and is primarily produced by T cells and mast cells. IL-4 promotes proliferation of B cells and cytotoxic T cells and stimulates IgG and IgE production [97], besides stimulating leukocytes recruitment and promoting the expression of adhesion molecules [127]. Increased levels of this cytokine were associated with greater impairments in nonverbal communication [120]. In ASD subjects, reduced level of IL-4 in n-DBSS [121] and elevated levels in amniotic fluid [128] have been reported.

20 *IL-5* 

21 IL-5 is a cytokine produced by T cells that acts as an activator of 22 eosinophils [129]. IL-5 promotes eosinophil proliferation and maturation,

stimulating IgA and IgM production [97]. In ASD patients, a decrease in IL-5 in nDBSS [121] and an increase in plasma samples [115] were described.

3 *IL-*6

The main source of IL-6 are T-helper cells, macrophages and fibroblasts. IL-6 targets activated B-cells and plasma cells, promoting differentiation into plasma cells and IgG production [97]. IL-6 is also involved in induction of Th17 response and has a dual profile pro- and anti-inflammatory [112,113]. Studies have demonstrated essential involvement of IL-6 in triggering core symptoms related to pro-inflammatory response in autistic model of maternal immune activation (MIA) [130].

Increased levels of IL-6 are associated with increased stereotypy in ASD 11 12 [120], impaired cognitive abilities, abnormal anxiety and decreased social 13 interactions [107]. Here, we review the main findings about IL-6 levels in ASD: IL-14 6 is elevated in brain tissue (cerebellum, frontal cortex and anterior cingulated 15 gyrus) [7,131,132], and in serum and PBMC [116-120], while it is reduced in 16 plasma and n-DBSS [114,121]. In the VPA animal model of autism, higher levels of IL-6 were reported in hippocampus [123], hippocampus and spleen after LPS 17 18 challenge [109] and whole brain homogenate [124].

19 *IL-8* 

Interleukin-8 is a chemoattractant cytokine produced mainly by macrophages that specifically targets neutrophils, promoting their activation [133]. So, its major functions result from its chemotactic and pro-inflammatory activities [97]. Elevated levels of this cytokine were associated with increased

hyperactivity, stereotypy, and lethargy [120]. Higher levels of IL-8 was described
in frontal cortex [132], plasma [115], cerebrospinal fluid (CSF) [134], PBMCs [120]
and n-DBSS [121] of ASD subjects.

4 *IL-10* 

5 This cytokine can be produced by several cellular types including DCs, 6 macrophages, mast cells, NK cells, eosinophils, neutrophils and B cells [135], 7 and is able to regulate growth and/or differentiation of B cells, NK cells, cytotoxic 8 and helper T cells, mast cells, granulocytes, dendritic cells, keratinocytes, and 9 endothelial cells, exerting a primarily anti-inflammatory activity [97,135]. IL-10 is 10 important to fine tune the immune response against invading pathogens, 11 maintaining the homeostatic state [135]. In ASD patients, increased levels to IL-12 10 were found in anterior cingulated gyrus and amniotic fluid [128,134], while IL-10 levels is decreased in PBMCs [96]. 13

14 *IL-12* 

IL-12 is produced by T cell and acts in naïve T-cells and NK cells, activating them [97], and inducing IFNγ production, which is critical for the induction of Th1 cells [136]. Plasma, PBMCs and serum of ASD subjects show higher levels of IL-12 [115,117,120] whereas n-DBSS show lower IL-12 levels [121]. Increased IL-12 levels were associated with increased stereotypy and lethargy in ASD patients [120].

21 *IL-13* 

Similarly to IL-4, IL-13 is involved in type-2 immunity and is produced by
T-cells. However, basophils, eosinophils and NK cells can also produce IL-13
[137]. The only report in autistic patients shows increased plasma levels of IL-13
[115].

5 IL-17

6 Interleukin-17 has an important role in immunity against intra and 7 extracellular pathogens [138]. IL-17-producing cells including natural killer T cells 8 and innate lymphoid cells play crucial roles in inflammation-associated diseases, 9 such as infection, autoimmunity and tumors [139]. Also was described the effector 10 role of IL-17a in onset of offspring behavioral abnormalities of mothers MIA-11 induced, showing the important crosstalk between the neuroinflammatory state 12 and behavioral manifestations [140]. Increase levels of IL-17 have been reported 13 in plasma and serum [115,141] of patients with ASD.

14 *IL-23* 

15 Considered a pro-inflammatory cytokine essential for the differentiation of 16 Th17 lymphocytes [142], IL-23 is produced by macrophages, dendritic cells, 17 keratinocytes and other antigen-presenting cells after recognition of 18 microorganisms [143]. IL-23 is critically involved in autoimmune diseases 19 responses [144]. In autistic patients, elevated IL-23 levels in serum samples were 20 reported [117].

21 *TNF-α* 

1 The tumor necrosis factor alpha (TNF $\alpha$ ) is an endotoxin-induced serum 2 factor promoting phagocyte cell activation [97], whose main targets and 3 producers are macrophages. TNF $\alpha$  is in higher levels both in patients (frontal 4 cortex [132], PBMC [96,118,119,145], serum [117] and amniotic fluid [128]) and 5 in the VPA animal model of autism (hippocampus and spleen responding to LPS 6 [109] and whole brain tissue [124]).

7 IFN-γ

Interferon-γ (IFN-γ) plays an important role in host defense against
intracellular pathogens. It is produced by NK T cells, CD8+ T cells, and T-helper
1 (Th1) CD4+ T cells and its functions include supporting Th1 differentiation [146],
and macrophage activation and increasing neutrophil and monocyte function [97].
Patients with ASD have increased levels of IFN-γ in frontal cortex [132], plasma
[147], CSF [134] and PBMC [96] and reduced levels in n-DBSS [121].

14 *TGFβ1* 

15 TGF- $\beta$  is primarily secreted by T cells and B cells, and acts in activated T 16 and B cells. The major function of this cytokine is to inhibit hematopoiesis and T 17 and B cell proliferation [97]. Higher levels to TGF $\beta$ 1 were reported in anterior 18 cingulated gyrus and CSF [134] of ASD subjects.

19 *MCP-1* 

20 Monocyte Chemoattractant Protein-1 (MCP-1) or C-C chemokine ligand 2 21 (CCL2) signals to cells that contain the specific CCR2 receptor, stimulating their 22 migration to sites where CCL2 is produced and facilitating the amplification of

neuroinflammation [148]. Higher levels of MCP-1 were observed in plasma [149],
CSF [134] and amniotic fluid [128] of autistic subjects. Increased levels in plasma
were associated with greater impairments in visual reception, fine motor skills
and expressive language [149].

5 GM-CSF

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is produced
by T cells, macrophages and fibroblasts and targets stem cells. Its major function
is to stimulate production of granulocyte, monocyte and eosinophils [97].
Diminished levels of GM-CSF were described in n-DBSS of ASD pediatric
subjects [121].

11 G-CSF

The main source of granulocyte colony-stimulating factor (G-CSF) are fibroblasts and endothelial cells and its targets are stem cells in the bone marrow. G-CSF has a hematopoietic function and stimulates granulocyte production [97]. Higher levels of this cytokine were described in plasma of autistic patients [114].

16 *EGF* 

Epidermal growth factor (EGF) is a small chemoattractant peptide produced by activated T cells that is involved with wound healing by attracting fibroblasts and epithelial cells [114]. Higher levels of this chemokine were reported in plasma samples from autistic patients [114].

21 RANTES

1 Regulated on Activation, Normal T-cell Expressed and Secreted 2 (RANTES) chemokine or CCL5 is involved in immune cell transport to the 3 inflammation site, promoting polarization towards an Th1 response [150]. Higher 4 levels were associated with increased severity of lethargy, stereotypy and 5 hyperactivity [149] in ASD patients.

6 Eotaxin

The CC chemokine eotaxin/CCL11 is known to bind to the receptor CCR3
on eosinophils and Th2-type lymphocytes [151]. Increased levels of Eotaxin were
associated with increased severity of lethargy, stereotypy and hyperactivity in
ASD subjects [149].

#### 11 Final considerations

12 Autistic Spectrum Disorder has a high prevalence and a growing incidence 13 over the last few years. This has driven investments in public health and 14 mobilized researchers and health professionals worldwide. There has been a significant progress in ASD research since the disorder was first described, but 15 16 to date, its etiology remains unclear. An interesting hypothesis is that dysregulation of neuroimmune communication is involved in the onset of ASD. In 17 18 this review, we summarized the main neuroimmune alterations found both in ASD 19 subjects and in the VPA animal model of autism. Noticeably, several changes in 20 the VPA model reflect the alterations found in patients with ASD (Figure 2). Animal models that present face and construct validity, such as the VPA model, 21 22 can be an effective tool for the investigation of pathways and tissue alterations involved with the pathogenesis of ASD. 23

## 1 Acknowledgments

This work was supported by development agencies: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (Capes) e Instituto Nacional de Ciência e Tecnologia em NeurolmunoModulação (INCT-NIM). The authors have no conflicts of interest.

#### 7 References

- Leo Kanner: Autistic disturbance of affective contact. Pathology 1943
   [cited 2018 Jan 27];2:217–250.
- 10 2 APA American Psychiatric Association: DSM-5 Diagnostic Classification;
- 11 in : Diagnostic and Statistical Manual of Mental Disorders. American
- 12 Psychiatric Association, 2013. DOI:
- 13 10.1176/appi.books.9780890425596.x00DiagnosticClassification
- 14 3 Huerta M, Lord C: Diagnostic Evaluation of Autism Spectrum Disorders.
- 15 Pediatr Clin North Am 2012;103–111.
- Gadia CA, Tuchman R, Rotta NT: Autismo e doenças invasivas de
  desenvolvimento. J Pediatr 2004 [cited 2018 Jan 27];S83–S94.
- 18 5 Rapin I, Tuchman RF: Autism: Definition, Neurobiology, Screening,
- 19 Diagnosis. Pediatr Clin North Am 2008;55:1129–1146.
- 20 6 Tonhajzerova I, Ondrejka I, Mestanik M, Mikolka P, Hrtanek I,
- 21 Mestanikova A, et al.: Inflammatory Activity in Autism Spectrum Disorder;
- in : Advances in experimental medicine and biology. 2015, pp 93–98.
- 23 7 Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA:

1		Neuroglial activation and neuroinflammation in the brain of patients with
2		autism. Ann Neurol 2005;57:67–81.
3	8	Autism Spectrum Disorders Working Group of The Psychiatric Genomics
4		Consortium TASDWG of TPG: Meta-analysis of GWAS of over 16,000
5		individuals with autism spectrum disorder highlights a novel locus at
6		10q24.32 and a significant overlap with schizophrenia. Mol Autism
7		2017;8:21.
8	9	Lintas C, Sacco R, Persico AM: Genome-wide expression studies in
9		Autism spectrum disorder, Rett syndrome, and Down syndrome.
10		Neurobiol Dis 2012;45:57–68.
11	10	Skafidas E, Testa R, Zantomio D, Chana G, Everall IP, Pantelis C:
12		Predicting the diagnosis of autism spectrum disorder using gene pathway
13		analysis. Mol Psychiatry 2014;19:504–510.
14	11	Christensen DL, Baio J, Braun KVN, Bilder D, Charles J, Constantino JN,
15		et al.: Prevalence and Characteristics of Autism Spectrum Disorder
16		Among Children Aged 8 Years — Autism and Developmental Disabilities
17		Monitoring Network, 11 Sites, United States, 2012. MMWR Surveill Summ
18		2016;65:1–23.
19	12	Smith V, Brown N: Prenatal valproate exposure and risk of autism
20		spectrum disorders and childhood autism. Arch Dis Child Educ Pract Ed
21		2014;99:198.
22	13	Roullet FI, Lai JKY, Foster JA: In utero exposure to valproic acid and
23		autism - A current review of clinical and animal studies. Neurotoxicol
24		Teratol 2013;36:47–56.

1	14	Ranger P, Ellenbroek BA: Perinatal Influences of Valproate on Brain and
2		Behaviour: An Animal Model for Autism; in : Current topics in behavioral
3		neurosciences. 2015, pp 363–386.
4	15	Christianson AL, Chester N, Kromberg JGR: Fetal Valproate Syndrome:
5		Clinical and Neuro-developmental Features in Two Sibling Pairs. Dev
6		Med Child Neurol 1994;36:361–369.
7	16	Moore SJ, Turnpenny P, Quinn A, Glover S, Lloyd DJ, Montgomery T, et
8		al.: A clinical study of 57 children with fetal anticonvulsant syndromes. J
9		Med Genet 2000 [cited 2018 Jan 29];37:489–497.
10	17	Williams G, King J, Cunningham M, Stephan M, Kerr B, Hersh JH: Fetal
11		valproate syndrome and autism: additional evidence of an association.
12		Dev Med Child Neurol 2001;43:202–206.
13	18	Williams PG, Hersh JH: A male with fetal valproate syndrome and autism.
14		Dev Med Child Neurol 1997;39:632–634.
15	19	Bambini-Junior V, Rodrigues L, Behr GA, Moreira JCF, Riesgo R,
16		Gottfried C: Animal model of autism induced by prenatal exposure to
17		valproate: behavioral changes and liver parameters. Brain Res
18		2011;1408:8–16.
19	20	Schneider T, Przewłocki R: Behavioral Alterations in Rats Prenatally
20		Exposed to Valproic Acid: Animal Model of Autism.
21		Neuropsychopharmacology 2005;30:80-89.
22	21	Schneider T, Roman A, Basta-Kaim A, Kubera M, Budziszewska B,
23		Schneider K, et al.: Gender-specific behavioral and immunological
24		alterations in an animal model of autism induced by prenatal exposure to

1		valproic acid. Psychoneuroendocrinology 2008;33:728–740.
2	22	Roullet FI, Wollaston L, Decatanzaro D, Foster JA: Behavioral and
3		molecular changes in the mouse in response to prenatal exposure to the
4		anti-epileptic drug valproic acid. Neuroscience 2010;170:514–22.
5	23	Baronio D, Castro K, Gonchoroski T, de Melo GM, Nunes GDF, Bambini-
6		Junior V, et al.: Effects of an H3R Antagonist on the Animal Model of
7		Autism Induced by Prenatal Exposure to Valproic Acid. PLoS One
8		2015;10:e0116363.
9	24	Favre MR, Barkat TR, Lamendola D, Khazen G, Markram H, Markram K:
10		General developmental health in the VPA-rat model of autism. Front
11		Behav Neurosci 2013;7:88.
12	25	Kataoka S, Takuma K, Hara Y, Maeda Y, Ago Y, Matsuda T: Autism-like
13		behaviours with transient histone hyperacetylation in mice treated
14		prenatally with valproic acid. Int J Neuropsychopharmacol 2013;16:91-
15		103.
16	26	Zhubi A, Cook EH, Guidotti A, Grayson DR: Epigenetic mechanisms in
17		autism spectrum disorder. ed 1 Elsevier Inc., 2014. DOI: 10.1016/B978-0-
18		12-801311-3.00006-8
19	27	Uher R: Gene-environment interactions in severe mental illness. Front
20		psychiatry 2014;5:48.
21	28	Misztak P, Pańczyszyn-Trzewik P, Sowa-Kućma M: Histone deacetylases
22		(HDACs) as therapeutic target for depressive disorders. Pharmacol
23		Reports 2018;70:398–408.
24	29	Koprinarova M, Schnekenburger M, Diederich M: Role of Histone

1	Acetylation in Cell Cycle Regulation. Curr Top Med Chem 2015;16:732-
2	744.

3	30	Nadal S, Raj R, Mohammed S, Davis BG: Synthetic post-translational
4		modification of histones. Curr Opin Chem Biol 2018;45:35–47.
5	31	Hu Y, Suliman BA: Roles of HDACs in the Responses of Innate Immune
6		Cells and as Targets in Inflammatory Diseases. Adv Exp Med Biol
7		2017;1024:91–110.
8	32	Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C,
9		et al.: Activation of MHC class I, II, and CD40 gene expression by histone
10		deacetylase inhibitors. J Immunol 2000 [cited 2018 Mar 18];165:7017-24.
11	33	Kroesen M, Gielen PR, Brok IC, Armandari I, Hoogerbrugge PM, Adema
12		GJ: HDAC inhibitors and immunotherapy; a double edged sword?
13		Oncotarget 2014;5:6558–6572.
14	34	Kawanai T, Ago Y, Watanabe R, Inoue A, Taruta A, Onaka Y, et al.:
15		Prenatal Exposure to Histone Deacetylase Inhibitors Affects Gene
16		Expression of Autism-Related Molecules and Delays Neuronal
17		Maturation. Neurochem Res 2016;41:2574–2584.
18	35	Marchetto MC, Belinson H, Tian Y, Freitas BC, Fu C, Vadodaria K, et al.:
19		Altered proliferation and networks in neural cells derived from idiopathic
20		autistic individuals. Mol Psychiatry 2017;22:820–835.
21	36	Kazlauskas N, Campolongo M, Lucchina L, Zappala C, Depino AM:
22		Postnatal behavioral and inflammatory alterations in female pups
23		prenatally exposed to valproic acid. Psychoneuroendocrinology
24		2016;72:11–21.

1	37	Lee HJ, Dreyfus C, DiCicco-Bloom E: Valproic acid stimulates
2		proliferation of glial precursors during cortical gliogenesis in developing
3		rat. Dev Neurobiol 2016;76:780–798.
4	38	Perisic T, Zimmermann N, Kirmeier T, Asmus M, Tuorto F, Uhr M, et al.:
5		Valproate and amitriptyline exert common and divergent influences on
6		global and gene promoter-specific chromatin modifications in rat primary
7		astrocytes. Neuropsychopharmacology 2010;35:792-805.
8	39	Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, et al.:
9		Valproic acid defines a novel class of HDAC inhibitors inducing
10		differentiation of transformed cells. EMBO J 2001;20:6969–78.
11	40	Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, et
12		al.: Structural and functional features of central nervous system lymphatic
13		vessels. Nature 2015;523:337-41.
14	41	Louveau A, Harris TH, Kipnis J: Revisiting the Mechanisms of CNS
15		Immune Privilege. Trends Immunol 2015;36:569–577.
16	42	Daneman R, Prat A: The blood-brain barrier. Cold Spring Harb Perspect
17		Biol 2015;7:a020412.
18	43	Wang Y, Rattner A, Zhou Y, Williams J, Smallwood PM, Nathans J:
19		Norrin/Frizzled4 Signaling in Retinal Vascular Development and Blood
20		Brain Barrier Plasticity. Cell 2012;151:1332–1344.
21	44	Zhou Y, Nathans J: Gpr124 Controls CNS Angiogenesis and Blood-Brain
22		Barrier Integrity by Promoting Ligand-Specific Canonical Wnt Signaling.
23		Dev Cell 2014;31:248–256.
24	45	Zhou Y, Wang Y, Tischfield M, Williams J, Smallwood PM, Rattner A, et

1		al.: Canonical WNT signaling components in vascular development and
2		barrier formation. J Clin Invest 2014;124:3825–3846.
3	46	Hagan N, Ben-Zvi A: The molecular, cellular, and morphological
4		components of blood-brain barrier development during embryogenesis.
5		Semin Cell Dev Biol 2015;38:7–15.
6	47	Zhao Z, Nelson AR, Betsholtz C, Zlokovic B V: Establishment and
7		Dysfunction of the Blood-Brain Barrier. Cell 2015;163:1064–1078.
8	48	Daneman R, Zhou L, Kebede AA, Barres BA: Pericytes are required for
9		blood-brain barrier integrity during embryogenesis. Nature
10		2010;468:562–566.
11	49	Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, et al.:
12		Pericytes Control Key Neurovascular Functions and Neuronal Phenotype
13		in the Adult Brain and during Brain Aging. Neuron 2010;68:409–427.
14	50	Li Q, Barres BA: Microglia and macrophages in brain homeostasis and
15		disease. Nat Rev Immunol 2017; DOI: 10.1038/nri.2017.125
16	51	Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely
17		G, et al.: Identification of a unique TGF- $\beta$ -dependent molecular and
18		functional signature in microglia. Nat Neurosci 2014;17:131–143.
19	52	Bohlen CJ, Bennett FC, Tucker AF, Collins HY, Mulinyawe SB, Barres
20		BA: Diverse Requirements for Microglial Survival, Specification, and
21		Function Revealed by Defined-Medium Cultures. Neuron 2017;94:759–
22		773.e8.
23	53	Kreutzberg GW: Microglia: a sensor for pathological events in the CNS.
24		Trends Neurosci 1996 [cited 2018 Mar 23];19:312–8.

1	54	Raivich G, Banati R: Brain microglia and blood-derived macrophages:
2		molecular profiles and functional roles in multiple sclerosis and animal
3		models of autoimmune demyelinating disease. Brain Res Rev
4		2004;46:261–281.
5	55	Nimmerjahn A, Kirchhoff F, Helmchen F: Resting Microglial Cells Are
6		Highly Dynamic Surveillants of Brain Parenchyma in Vivo. Science (80-)
7		2005;308:1314–1318.
8	56	Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J: Resting
9		Microglia Directly Monitor the Functional State of Synapses In Vivo and
10		Determine the Fate of Ischemic Terminals. J Neurosci 2009;29:3974-
11		3980.
12	57	Olson JK, Miller SD: Microglia initiate central nervous system innate and
13		adaptive immune responses through multiple TLRs. J Immunol 2004
14		[cited 2018 Mar 23];173:3916–24.
15	58	Buttgereit A, Lelios I, Yu X, Vrohlings M, Krakoski NR, Gautier EL, et al.:
16		Sall1 is a transcriptional regulator defining microglia identity and function.
17		Nat Immunol 2016;17:1397–1406.
18	59	Parisi C, Napoli G, Pelegrin P, Volonté C: M1 and M2 Functional
19		Imprinting of Primary Microglia: Role of P2X7 Activation and miR-125b.
20		Mediators Inflamm 2016;2016:2989548.
21	60	Hanisch U-K, Prinz M, Angstwurm K, Hausler KG, Kann O, Kettenmann
22		H, et al.: The protein tyrosine kinase inhibitor AG126prevents the massive
23		microglial cytokine inductionby pneumococcal cell walls. Eur J Immunol
24		2001 [cited 2018 Mar 23];31:2104–2115.

1	61	Häusler KG, Prinz M, Nolte C, Weber JR, Schumann RR, Kettenmann H,
2		et al.: Interferon-gamma differentially modulates the release of cytokines
3		and chemokines in lipopolysaccharide- and pneumococcal cell wall-
4		stimulated mouse microglia and macrophages. Eur J Neurosci 2002 [cited
5		2018 Mar 23];16:2113–22.
6	62	Škuljec J, Sun H, Pul R, Bénardais K, Ragancokova D, Moharregh-
7		Khiabani D, et al.: CCL5 induces a pro-inflammatory profile in microglia in
8		vitro. Cell Immunol 2011;270:164–171.
9	63	Zarruk JG, Greenhalgh AD, David S: Microglia and macrophages differ in
10		their inflammatory profile after permanent brain ischemia. Exp Neurol
11		2018;301:120–132.
12	64	Hu X, Leak RK, Shi Y, Suenaga J, Gao Y, Zheng P, et al.: Microglial and
13		macrophage polarization—new prospects for brain repair. Nat Rev Neurol
14		2015;11:56–64.
15	65	Hanisch U-K, Kettenmann H: Microglia: active sensor and versatile
16		effector cells in the normal and pathologic brain. Nat Neurosci
17		2007;10:1387–1394.
18	66	Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, et
19		al.: Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial
20		Activation States and Aspects of Alzheimer's Disease Not Evident in
21		Mouse Models. Cell Rep 2018;22:832–847.
22	67	Koyama R, Ikegaya Y: Microglia in the pathogenesis of autism spectrum
23		disorders. Neurosci Res 2015;100:1–5.
24	68	Hansen D V., Hanson JE, Sheng M: Microglia in Alzheimer's disease. J

1 Cell Biol 2018;217:459–472.

2	69	Lucchinetti CF, Popescu BFG, Bunyan RF, Moll NM, Roemer SF,
3		Lassmann H, et al.: Inflammatory Cortical Demyelination in Early Multiple
4		Sclerosis. N Engl J Med 2011;365:2188–2197.
5	70	Antonietta Ajmone-Cat M, Mancini M, De Simone R, Cilli P, Minghetti L:
6		Microglial polarization and plasticity: Evidence from organotypic
7		hippocampal slice cultures. Glia 2013;61:1698–1711.
8	71	Serhan CN, Savill J: Resolution of inflammation: the beginning programs
9		the end. Nat Immunol 2005;6:1191–1197.
10	72	Herz J, Filiano AJ, Smith A, Yogev N, Kipnis J: Myeloid Cells in the
11		Central Nervous System. Immun Rev 2017; DOI:
12		10.1016/j.immuni.2017.06.007
13	73	Serrats J, Schiltz JC, García-Bueno B, van Rooijen N, Reyes TM,
14		Sawchenko PE: Dual Roles for Perivascular Macrophages in Immune-to-
15		Brain Signaling. Neuron 2010;65:94–106.
16	74	Williams K, Alvarez X, Lackner AA: Central nervous system perivascular
17		cells are immunoregulatory cells that connect the CNS with the peripheral
18		immune system. Glia 2001 [cited 2018 Mar 23];36:156–64.
19	75	He H, Mack JJ, Güç E, Warren CM, Squadrito ML, Kilarski WW, et al.:
20		Perivascular Macrophages Limit PermeabilityHighlights. Arterioscler
21		Thromb Vasc Biol 2016;36:2203–2212.
22	76	Shechter R, London A, Schwartz M: Orchestrated leukocyte recruitment
23		to immune-privileged sites: absolute barriers versus educational gates.
24		Nat Rev Immunol 2013;13:206–218.

1	77	Quintana E, Fernández A, Velasco P, de Andrés B, Liste I, Sancho D, et
2		al.: DNGR-1 + dendritic cells are located in meningeal membrane and
3		choroid plexus of the noninjured brain. Glia 2015;63:2231–2248.
4	78	Meeker RB, Williams K, Killebrew DA, Hudson LC: Cell trafficking through
5		the choroid plexus. Cell Adh Migr 2012;6:390–6.
6	79	Mendez-Gomez HR, Galera-Prat A, Meyers C, Chen W, Carrion-Vazquez
7		M, Muzyczka N: Crossing the Blood-Cerebrospinal Fluid Barrier in the
8		Mouse Choroid Plexus With an Engineered Receptor/Ligand System. Mol
9		Ther 2015;23:S65.
10	80	Kierdorf K, Prinz M, Gomez Perdiguero E: Development and function of
11		tissue resident macrophages in mice. Semin Immunol 2015;27:369–378.
12	81	Roth TL, Nayak D, Atanasijevic T, Koretsky AP, Latour LL, McGavern DB:
13		Transcranial amelioration of inflammation and cell death after brain injury.
14		Nature 2014;505:223–228.
15	82	Mildner A, Mack M, Schmidt H, Brück W, Djukic M, Zabel MD, et al.:
16		CCR2+Ly-6Chi monocytes are crucial for the effector phase of
17		autoimmunity in the central nervous system. Brain 2009;132:2487-2500.
18	83	Dong H, Zhang X, Qian Y: Mast cells and neuroinflammation. Med Sci
19		Monit Basic Res 2014;20:200–6.
20	84	Prinz M, Priller J: The role of peripheral immune cells in the CNS in
21		steady state and disease. Nat Neurosci 2017;20:136–144.
22	85	Nau R, Zettl U, Gerber J, Trostdorf F, Michel U, Böttcher T, et al.:
23		Granulocytes in the subarachnoid space of humans and rabbits with
24		bacterial meningitis undergo apoptosis and are eliminated by

1	macrophages.	Acta Neuropatho	l 1998;96:472–480.
---	--------------	-----------------	--------------------

2	86	McMenamin PG, Wealthall RJ, Deverall M, Cooper SJ, Griffin B:
3		Macrophages and dendritic cells in the rat meninges and choroid plexus:
4		three-dimensional localisation by environmental scanning electron
5		microscopy and confocal microscopy. Cell Tissue Res 2003;313:259-
6		269.
7	87	Chinnery HR, Ruitenberg MJ, McMenamin PG: Novel Characterization of
8		Monocyte-Derived Cell Populations in the Meninges and Choroid Plexus
9		and Their Rates of Replenishment in Bone Marrow Chimeric Mice. J
10		Neuropathol Exp Neurol 2010;69:896–909.
11	88	Anandasabapathy N, Victora GD, Meredith M, Feder R, Dong B, Kluger
12		C, et al.: Flt3L controls the development of radiosensitive dendritic cells in
13		the meninges and choroid plexus of the steady-state mouse brain. J Exp
14		Med 2011;208:1695–1705.
15	89	Prendergast CT, Anderton SM: Immune cell entry to central nervous
16		systemcurrent understanding and prospective therapeutic targets.
17		Endocr Metab Immune Disord Drug Targets 2009 [cited 2018 Mar
18		23];9:315–27.
19	90	Fabis MJ, Phares TW, Kean RB, Koprowski H, Hooper DC: Blood– brain
20		barrier changes and cell invasion differ between therapeutic immune
21		clearance of neurotrophic virus and CNS autoimmunity. PNAS 2008 [cited
22		2018 Mar 23];Available from:
23		http://www.pnas.org/content/pnas/105/40/15511.full.pdf
24	91	Arima Y, Kamimura D, Sabharwal L, Yamada M, Bando H, Ogura H, et

1		al.: Regulation of immune cell infiltration into the CNS by regional neural
2		inputs explained by the gate theory. Mediators Inflamm
3		2013;2013:898165.
4	92	Dendrou CA, Fugger L, Friese MA: Immunopathology of multiple
5		sclerosis. Nat Rev Immunol 2015;15:545–558.
6	93	da Fonseca ACC, Matias D, Garcia C, Amaral R, Geraldo LH, Freitas C,
7		et al.: The impact of microglial activation on blood-brain barrier in brain
8		diseases. Front Cell Neurosci 2014;8:362.
9	94	Phares TW, Kean RB, Mikheeva T, Hooper DC: Regional Differences in
10		Blood-Brain Barrier Permeability Changes and Inflammation in the
11		Apathogenic Clearance of Virus from the Central Nervous System. J
12		Immunol 2006;114:1761–5.
13	95	Bilbo SD, Block CL, Bolton JL, Hanamsagar R, Tran PK: Beyond infection
14		- Maternal immune activation by environmental factors, microglial
15		development, and relevance for autism spectrum disorders. Exp Neurol
16		2018;299:241–251.
17	96	Ashwood P, Wills S, Van de Water J: The immune response in autism: a
18		new frontier for autism research. J Leukoc Biol 2006;80:1–15.
19	97	Turner MD, Nedjai B, Hurst T, Pennington DJ: Cytokines and
20		chemokines: At the crossroads of cell signalling and inflammatory
21		disease. Biochim Biophys Acta 2014;1843:2563–2582.
22	98	Masi A, Glozier N, Dale R, Guastella AJ: The Immune System, Cytokines,
23		and Biomarkers in Autism Spectrum Disorder. Neurosci Bull
24		2017;33:194–204.

1	99	Ramesh G, MacLean AG, Philipp MT: Cytokines and chemokines at the
2		crossroads of neuroinflammation, neurodegeneration, and neuropathic
3		pain. Mediators Inflamm 2013;2013:480739.
4	100	Biber K, Vinet J, Boddeke HWGM: Neuron-microglia signaling:
5		Chemokines as versatile messengers. J Neuroimmunol 2008;198:69–74.
6	101	Réaux-Le Goazigo A, Van Steenwinckel J, Rostène W, Mélik
7		Parsadaniantz S: Current status of chemokines in the adult CNS. Prog
8		Neurobiol 2013;104:67–92.
9	102	Charles A Janeway J, Travers P, Walport M, Shlomchik MJ:
10		Immunobiology: The Immune System in Health and Disease. Garland
11		Science, 2001, [cited 2018 Mar 18]. Available from:
12		https://www.ncbi.nlm.nih.gov/books/NBK27092/
13	103	Metz DP, Bottomly K: Function and regulation of memory CD4 T cells.
14		Immunol Res 1999;19:127–141.
15	104	Amedei A, Prisco D, D'Elios M: Multiple Sclerosis: The Role of Cytokines
16		in Pathogenesis and in Therapies. Int J Mol Sci 2012;13:13438–13460.
17	105	Vijayakumar NT, Judy M V.: Autism spectrum disorders: Integration of the
18		genome, transcriptome and the environment. J Neurol Sci 2016; DOI:
19		10.1016/j.jns.2016.03.026
20	106	Erta M, Giralt M, Esposito FL, Fernandez-Gayol O, Hidalgo J: Astrocytic
21		IL-6 mediates locomotor activity, exploration, anxiety, learning and social
22		behavior. Horm Behav 2015;73:64–74.
23	107	Wei H, Chadman KK, McCloskey DP, Sheikh AM, Malik M, Brown WT, et
24		al.: Brain IL-6 elevation causes neuronal circuitry imbalances and

1		mediates autism-like behaviors. Biochim Biophys Acta - Mol Basis Dis
2		2012;1822:831–842.
3	108	Bluthé RM, Michaud B, Poli V, Dantzer R: Role of IL-6 in cytokine-induced
4		sickness behavior: a study with IL-6 deficient mice. Physiol Behav 2000
5		[cited 2018 Mar 19];70:367–73.
6	109	Lucchina L, Depino AM: Altered Peripheral and Central Inflammatory
7		Responses in a Mouse Model of Autism. Autism Res 2013;7:273–289.
8	110	Gottfried C, Bambini-Junior V, Francis F, Riesgo R, Savino W: The
9		Impact of Neuroimmune Alterations in Autism Spectrum Disorder. Front
10		psychiatry 2015;6:121.
11	111	Musolino C, Allegra A, Innao V, Allegra AG, Pioggia G, Gangemi S:
12		Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and
13		Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma.
14		Mediators Inflamm 2017;2017:1852517.
15	112	Dinarello CA: Immunological and Inflammatory Functions of the
16		Interleukin-1 Family. Annu Rev Immunol 2009;27:519–550.
17	113	Gray SM, Bloch MH: Systematic review of proinflammatory cytokines in
18		obsessive-compulsive disorder. Curr Psychiatry Rep 2012;14:220–8.
19	114	Manzardo AM, Henkhaus R, Dhillon S, Butler MG: Plasma cytokine levels
20		in children with autistic disorder and unrelated siblings. Int J Dev Neurosci
21		2012;30:121–127.
22	115	Suzuki K, Matsuzaki H, Iwata K, Kameno Y, Shimmura C, Kawai S, et al.:
23		Plasma cytokine profiles in subjects with high-functioning autism
24		spectrum disorders. PLoS One 2011;6:1–6.

1	116	Emanuele E, Orsi P, Boso M, Broglia D, Brondino N, Barale F, et al.: Low-
2		grade endotoxemia in patients with severe autism. Neurosci Lett
3		2010;471:162–165.
4	117	Ricci S, Businaro R, Ippoliti F, Lo Vasco VR, Massoni F, Onofri E, et al.:
5		Altered cytokine and BDNF levels in autism spectrum disorder. Neurotox
6		Res 2013;24:491–501.
7	118	Enstrom AM, Onore CE, Van de Water JA, Ashwood P: Differential
8		monocyte responses to TLR ligands in children with autism spectrum
9		disorders. Brain Behav Immun 2010;24:64–71.
10	119	Jyonouchi H, Sun S, Le H: Proinflammatory and regulatory cytokine
11		production associated with innate and adaptive immune responses in
12		children with autism spectrum disorders and developmental regression. J
13		Neuroimmunol 2001;120:170–179.
14	120	Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de
15		Water J: Elevated plasma cytokines in autism spectrum disorders provide
16		evidence of immune dysfunction and are associated with impaired
17		behavioral outcome. Brain Behav Immun 2011;25:40–45.
18	121	Abdallah MW, Larsen N, Mortensen EL, Atladóttir HÓ, Nørgaard-
19		Pedersen B, Bonefeld-Jørgensen EC, et al.: Neonatal levels of cytokines
20		and risk of autism spectrum disorders: An exploratory register-based
21		historic birth cohort study utilizing the Danish Newborn Screening
22		Biobank. J Neuroimmunol 2012;252:75–82.
23	122	Theije CGM, Wu J, Koelink PJ, Korte-Bouws GAH, Borre Y, Kas MJH, et
24		al.: Autistic-like behavioural and neurochemical changes in a mouse

1		model of food allergy. Behav Brain Res 2014;261:265–274.
2	123	Wu H, Wang X, Gao J, Liang S, Hao Y, Sun C, et al.: Fingolimod
3		(FTY720) attenuates social deficits, learning and memory impairments,
4		neuronal loss and neuroinflammation in the rat model of autism. Life Sci
5		2017;173:43–54.
6	124	Hegazy HG, Ali EHA, Elgoly AHM: Interplay between pro-inflammatory
7		cytokines and brain oxidative stress biomarkers: Evidence of parallels
8		between butyl paraben intoxication and the valproic acid brain
9		physiopathology in autism rat model. Cytokine 2015;71:173–180.
10	125	Kelly E, Won A, Refaeli Y, Van Parijs L: IL-2 and related cytokines can
11		promote T cell survival by activating AKT. J Immunol 2002 [cited 2018
12		Mar 20];168:597–603.
13	126	Malek TR: The main function of IL-2 is to promote the development of T
14		regulatory cells. J Leukoc Biol 2003;74:961–965.
15	127	Fukuda T, Fukushima Y, Numao T, Ando N, Arima M, Nakajima H, et al.:
16		Role of interleukin-4 and vascular cell adhesion molecule-1 in selective
17		eosinophil migration into the airways in allergic asthma. Am J Respir Cell
18		Mol Biol 1996;14:84–94.
19	128	Abdallah MW, Larsen N, Grove J, Rgaard-pedersen BNØ, Thorsen P,
20		Mortensen EL, et al.: Amniotic fl uid infl ammatory cytokines : Potential
21		markers of immunologic dysfunction in autism spectrum disorders. World
22		J Biol Psychiatry 2013;528–538.
23	129	Greenfeder S, Umland SP, Cuss FM, Chapman RW, Egan RW: Th2
24		cytokines and asthma. The role of interleukin-5 in allergic eosinophilic

1 disease. Respir Res 2001;2:71-9. Smith SEP, Li J, Garbett K, Mirnics K, Patterson PH: Maternal Immune 2 130 3 Activation Alters Fetal Brain Development through Interleukin-6. J Neurosci 2007 [cited 2018 May 3]; Available from: 4 5 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2387067/pdf/nihms42804. 6 pdf 7 Wei H, Zou H, Sheikh AM, Malik M, Dobkin C, Brown WT, et al.: IL-6 is 131 increased in the cerebellum of autistic brain and alters neural cell 8 9 adhesion, migration and synaptic formation. J Neuroinflammation 2011;8:1–10. 10 132 Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM, et al.: Elevated 11 immune response in the brain of autistic patients. J Neuroimmunol 12 13 2009;207:111–116. 14 133 Bickel M: The role of interleukin-8 in inflammation and mechanisms of regulation. J Periodontol 1993 [cited 2018 Mar 20];64:456-60. 15 16 134 Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA: Neuroglial activation and neuroinflammation in the brain of patients with 17 autism. Ann Neurol 2005;57:67-81. 18 Ma X, Yan W, Zheng H, Du Q, Zhang L, Ban Y, et al.: Regulation of IL-10 19 135 and IL-12 production and function in macrophages and dendritic cells. 20 21 F1000Research 2015;4. DOI: 10.12688/f1000research.7010.1 22 136 Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A: The IL-12 family of 23 cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets 2009 [cited 2018 Mar 20];8:40-52. 24

1	137	Bao K, Reinhardt RL: The differential expression of IL-4 and IL-13 and its
2		impact on type-2 immunity. Cytokine 2015;75:25–37.
3	138	Kuwabara T, Ishikawa F, Kondo M, Kakiuchi T: The Role of IL-17 and
4		Related Cytokines in Inflammatory Autoimmune Diseases. Mediators
5		Inflamm 2017;2017:1–11.
6	139	ZHONG F, CUI D, TAO H, DU H, XING C: IL-17A-producing T cells and
7		associated cytokines are involved in the progression of gastric cancer.
8		Oncol Rep 2015;34:2365–2374.
9	140	Choi GB, Yim YS, Wong H, Kim S, Kim H, Kim S V, et al.: The maternal
10		interleukin-17a pathway in mice promotes autism-like phenotypes in
11		offspring. Science 2016;351:933–9.
12	141	AL-Ayadhi LY, Mostafa GA: Elevated serum levels of interleukin-17A in
13		children with autism. J Neuroinflammation 2012;9:595.
14	142	Toussirot E: The IL23/Th17 pathway as a therapeutic target in chronic
15		inflammatory diseases. Inflamm Allergy Drug Targets 2012 [cited 2018
16		Mar 20];11:159–68.
17	143	Fischer K, Przepiera-Będzak H, Sawicki M, Walecka A, Brzosko I,
18		Brzosko M: Serum Interleukin-23 in Polish Patients with Systemic Lupus
19		Erythematosus: Association with Lupus Nephritis, Obesity, and Peripheral
20		Vascular Disease. Mediators Inflamm 2017; DOI: 10.1155/2017/9401432
21	144	Ziblat A, Nuñez SY, Raffo Iraolagoitia XL, Spallanzani RG, Torres NI,
22		Sierra JM, et al.: Interleukin (IL)-23 Stimulates IFN-γ Secretion by
23		CD56bright Natural Killer Cells and Enhances IL-18-Driven Dendritic Cells
24		Activation. Front Immunol 2018;8:1959.

1	145	Jyonouchi H, Sun S, Itokazu N: Innate immunity associated with
2		inflammatory responses and cytokine production against common dietary
3		proteins in patients with autism spectrum disorder. Neuropsychobiology
4		2002;46:76–84.
5	146	Mah AY, Cooper MA: Metabolic Regulation of Natural Killer Cell IFN- $\gamma$
6		Production. Crit Rev Immunol 2016;36:131–147.
7	147	Tostes MHFS, Teixeira HC, Gattaz WF, Brandão MAF, Raposo NRB:
8		Altered neurotrophin, neuropeptide, cytokines and nitric oxide levels in
9		autism. Pharmacopsychiatry 2012;45:241–243.
10	148	Gutiérrez IL, González-Prieto M, García-Bueno B, Caso JR, Feinstein DL,
11		Madrigal JLM: CCL2 Induces the Production of $\beta$ 2 Adrenergic Receptors
12		and Modifies Astrocytic Responses to Noradrenaline. Mol Neurobiol
13		2018;1–14.
14	149	Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah IN, Van de
15		Water J: Associations of impaired behaviors with elevated plasma
16		chemokines in autism spectrum disorders. J Neuroimmunol 2011; DOI:
17		10.1016/j.jneuroim.2010.10.025
18	150	Fichna M, Żurawek M, Budny B, Komarowska H, Niechciał E, Fichna P, et
19		al.: Elevated serum RANTES chemokine in autoimmune Addison's
20		disease. Polish Arch Intern Med 2018; DOI: 10.20452/pamw.4221
21	151	Cheng SS, Lukacs NW, Kunkel SL: Eotaxin/CCL11 suppresses IL-
22		8/CXCL8 secretion from human dermal microvascular endothelial cells. J
23		Immunol 2002 [cited 2018 Mar 20];168:2887–94.
24	152	Ahmad SF, Zoheir KMA, Ansari MA, Nadeem A, Bakheet SA, AL-Ayadhi

1		LY, et al.: Dysregulation of Th1, Th2, Th17, and T regulatory cell-related
2		transcription factor signaling in children with autism. Mol Neurobiol
3		2017;54:4390–4400.
4	153	Ashwood P, Anthony A, Torrente F, Wakefield AJ: Spontaneous mucosal
5		lymphocyte cytokine profiles in children with autism and gastrointestinal
6		symptoms: Mucosal immune activation and reduced counter regulatory
7		interleukin-10. J Clin Immunol 2004;24:664–673.
8	154	Enstrom AM, Onore CE, Van de Water JA, Ashwood P: Differential
9		monocyte responses to TLR ligands in children with autism spectrum
10		disorders. Brain Behav Immun 2010;24:64–71.

DSM	Severity	Described comorbidities	Age (years)	Source	Outcome	Analysis method	Reference
ASD	ND	ND	neonatal	amniotic fluid	↑ MCP-1, IL-4, IL-10, TNF-α and TNF-β	Flow cytometry	[128]
ASD	ND	ND	neonatal	n-DBSS	↓ IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL- 12, GM-CSF, IFN-γ ↑ sIL-6Rα, IL-8	Flow cytometry	[121]
ASD (DSM-IV)	Mild, moderate and Severe	ND	2-21	Serum	↑ IL-1, IL-6, IL-12, IL-23, TNF-α	ELISA	[117]
ASD (DSM-5)	ND	ND	3-11	PBMCs	↓ CD4+, FOXP3+,  T cells ↓ mRNA and protein expression FoxP3 ↑ Tbet, ↑ STAT3, ↑ GATA3	Flow cytometry, PCR and Western Blotting	[152]
ASD (DSM-5)	ND	ND	3-11	PBMCs	↑ ROR-yt in CD4	PCR and Western Blotting	[152]
ASD (DSM- IIIR/DSM-IV)	ND	GI issues	2-16	Duodenal Lamina Propria	↑ CD3+/TNFα+ ↓ CD3+/IL-10+	Flow cytometry	[153]
ASD (DSM- IIIR/DSM-IV)	ND	GI issues	2-16	Epithelium	↑ CD3+/TNFα+ ↓ CD3+/IL-10+	Flow cytometry	[153]
ASD (DSM-IV)	ND	ND	1-17	PBMCs	↑ TNF-α	ELISA	[145]
ASD (DSM-IV)	ND	GI issues	4-15	PBMCs	↑ TNF-α, IFN-γ ↓ IL-10	Flow cytometry	[96]
ASD (DSM-IV)	Severe (nonverbal adult pacients)	ND	18-44	Serum	↑ IL-1β, IL-6	ELISA	[116]

# Table 1. Main cytokines with altered levels in autism subjects

ASD (DSM-IV)	ND	ND	2.9-4.3	PBMCs	↑ IL-1β, IL-6, IL-8, IL-12 p40	Multiplexing bead immunoassays	[120]
ASD (DSM-IV)	ND	ND	2-14	PBMCs	↑ TNF-α, TNFRI, TNFRII, IL-6, IL-1β	ELISA	[119]
ASD (DSM-IV)	ND	ND	2.2-5	PBMCs	↑ 1L-1β, IL-6, TNF-α	Flow citometry	[154]
ASD (DSM-IV)	ND	ND	5-44	<i>post mortem</i> brain tissue	↑ IL-6, IL10, TGFβ1 (anterior cingulated gyrus)	Human cytokine array kits	[7]
ASD (DSM-IV)	ND	ND	5-44	CSF	↑ IFNγ, TGFβ2, IL-8, MCP1	Human cytokine array kits	[7]
ASD (DSM-IV)	ND	ND	4-37	<i>post mortem</i> brain tissue	↑ IFNγ, IL-6, IL-8, TNF-α (frontal cortex)	Multiplex Bead Immunoassays	[132]
ASD (DSM-IV)	ND	ND	4-14	<i>post mortem</i> brain tissue	↑ IL-6 (cerebellum)	Immunohistochemistry	[131]
ASD (DSM-IV)	ND	ND	7-15	Plasma	↑ IL-1β, IL-1RA, IL-5, IL-8, IL-12 (p70), IL-13, IL-17	ELISA	[115]
ASD (DSM-IV)	ND	ND	3-4.5	Plasma	↑ MCP-1, RANTES, Eotaxin	Multiplexing bead immunoassays	[149]
ASD (DSM-IV)	ND	ND	4.7-10.1	Plasma	↑ IFN-γ	ELISA	[147]
ASD (DSM-IV)	Mild to moderate and Severe	ND	6-11	Serum	↑ IL-17A (proportional increase to severity of autism)	ELISA	[141]
ASD (DSM-IV)	ND	ND	5-10	Plasma	↑ IL-1a ↓ IL-6, G-CSF, EGF	ELISA	[114]

DSM: Diagnostic and Statistical Manual of Mental Disorders; CSF: cerebrospinal fluid; ELISA: enzyme-linked immunosorbent assay; IFN: interferon; IL: interleukin; ND: not described; n-DBSS: neonatal dried blood samples; PBMC: peripheral blood mononuclear cells; PCR: polymerase chain reaction; TNF: tumor necrosis factor.

Animal	Dosage	Embryonic day	Administration via	Source	Age	Outcome	Analysis method	References
BALB/c	600 mg/Kg	E11	Subcutaneous	Dorsal hippocampus	P28	↑ IL-1β	PCR	[122]
BALB/c	400 mg/Kg and 600 mg/Kg	E12.5	Subcutaneous	Spleen	8-10 weeks	Only VPA did not onset inflammatory response, but showed exacerbated response to a LPS challenge: $\uparrow$ IL-1 $\beta$ , IL-6 and TNF- $\alpha$ expression	PCR	[109]
BALB/c	400 mg/Kg and 600 mg/Kg	E12.5	Subcutaneous	Hippocampus/ Cerebellum	8-10 weeks	$\uparrow$ IL-6 and TNF-α expression in VPA animals exposed to a LPS challenge	PCR	[109]
Wistar	600 mg/Kg	E12.5	Intraperitoneal	Hippocampus	P40	↑ IL-6, ↑ IL-1β	ELISA	[123]
Wistar	800 mg/Kg	E12.5	Gavage	Whole brain	P21	↑ IL-1β, IL-6, TNF-α	ELISA	[124]

Table 2. Main cytokines with altered levels in the valproic acid animal model of autism

IL: interleukin; PCR: polymerase chain reaction.

**Figure 1. Th1, Th2, Th17 commitment lineage from naïve CD4+ T cells**. The main functions of each immune response and the signature cytokine are highlighted in the boxes. APC: antigen-presenting cell; NK: natural killer cell; T-bet: T box expressed in T cells; GATA: GATA-binding protein; ROR: Retinoid-related orphan receptor; IL: Interleukin; IFN: Interferon; TGF: Transforming growth factor.

**Figure 2. Main results of cytokines altered both in ASD subjects and in VPA animal model**. At the interface of the columns and rows are shown the common findings both to humans and to animal model in different biological sources. The references are already cited in Table 1.



Figure 1. Th1, Th2, Th17 commitment lineage from naïve CD4+ T cells.

Tissue	9		Peripheral			
↑ <b>IL-6</b> Cerebellum Frontal cortex Anterior cingulated gyrus	Subjects ↑ <b>IL-8</b> Frontal cortex	† IL-6 † IL-8 † IL-10 † TNFα † INFγ † TGFβ1	<b>IL-1β</b> ↑ Plasma ↑ Serum ↑ PBMC	↓ <b>IL-2</b> Dried blood	Subjects IL-4 ↓ Dried blood ↑ amniotic fluid	
↑ <b>IL-10</b> Anterior cingulated gyrus ↑ <b>TGFβ1</b> Anterior cingulated gyrus	↑ <b>IFNγ</b> Frontal cortex ↑ <b>TNFα</b> Frontal cortex		↓ Uned blood I <b>L-5</b> ↓ Dried blood ↑ Plasma	IL-6 ↓ Plasma ↓ Dried blood ↑ Serum ↑ PBMC	↑ <b>IL-8</b> Plasma CSF PBMC Dried blood	
↑ IL-6 ↑ TNF	α		<b>IL-10</b> ↓ PBMC ↑ amniotic fluid	IL-12 ↑ Plasma ↑ PBMC ↑ Serum ↓ Dried blood	↑ <b>IL-13</b> Plasma ↑ <b>TGFβ1</b>	
↑ <b>IL-1β</b> Hippocampus Hippocampus responding t Whole brain	Animal model		∱ <b>IL-17</b> Plasma Serum ↑ <b>TNFα</b>	↑ <b>IL-23</b> Serum <b>IFNγ</b> ↑ Plasma ↑ CSF ↑ PBMC ↓ Dried blood	↑ <b>MCP1</b> Plasma CSF Amniotic fluid	
↑ <b>IL-6</b> Hippocampus Hippocampus and Spleen r Whole brain	responding to LPS		PBMC Serum Amniotic fluid		↓ <b>GM-CSF</b> Dried blood	
↑ <b>TNFα</b> Hippocampus and Spleen r Whole brain	responding to LPS		↑ <b>G-CSF and EG</b> Plasma	F ∱ <b>RA</b> Plasi	NTES and Eotaxin ma	

Figure 2. Main results of cytokines altered both in ASD subjects and in VPA animal model.